Multiple Myeloma—The Great Masquerader: A Case Report and Narrative Review of Current Management Strategies

Authors

  • Dr. Liya K Babu DNB Resident, Department of General Medicine, Lourdes Hospital, Ernakulam, Kerala, India Author
  • Dr. Jophy Varghese Consultant Pathologist, JV’s Path Labs, Ernakulam, Kerala Author
  • Dr. Rajeev Zachariah Kompithra Physician, Department of Child Health, Christian Medical College and Hospital, Vellore Author
  • Dr. Joison Abraham Senior Physician and Diabetologist, Department of General Medicine, Lourdes Hospital, Ernakulam, Kerala, India Author

DOI:

https://doi.org/10.31305/rrijm.2026.v11.n11.001

Keywords:

Multiple myeloma, hypercalcemia, renal insufficiency, osteolysis, plasma cells, Multiple myeloma/diagnosis, Multiple myeloma/therapeutics, Multiple myeloma/trends

Abstract

Background: Multiple myeloma, the second commonest haematological malignancy, is characterized by clonal proliferation of bone marrow plasma cells, monoclonal protein production, and end-organ damage. Despite its classical clinical manifestations commonly summarized as the CRAB features viz. hyperCalcemia, Renal insufficiency, Anemia, and Bone lesions, it is among the most difficult cancers to diagnose – given its rarity, myriad symptom constellation which masquerade as common age-related or localized conditions leading to frequent diagnostic delays, besides alternative close differentials leading to misdiagnoses. Case report: A 74-year-old male presented with decreased oral intake and reduced verbal response for one week, constipation for two days, and acute urinary retention for one day. He had a three-month history of recurrent constipation, decreased appetite, fatigue, and agitated behavior. His medical history included type-2 diabetes mellitus, diabetic nephropathy, ischemic heart disease, hypothyroidism, and benign prostatic hyperplasia. A recent hospitalization had revealed hyperuricemia and acute kidney injury, which improved with conservative management. On examination, the patient was confused, disoriented, pale, dehydrated, and had pedal edema, without focal neurological deficits. Laboratory investigations revealed anemia (hemoglobin 9.3 g/dL) with markedly elevated ESR (120 mm/hour), markedly elevated urea (174 mg/dL) with serum creatinine (10.9 mg/dL), and elevated serum calcium (11.4 mg/dL), with a reported corrected calcium of 12.52 mg/dL. Serum albumin was 2.6 g/dL. Serum protein electrophoresis showed ‘M-spike’ of 6.30 g/dL. Skull radiography demonstrated punched out multiple lytic lesions. Bone marrow aspirate revealed plasma cells, and bone marrow biopsy showed plasmacytosis. Discussion: Despite findings consistent with Multiple myeloma with symptomatic end-organ involvement and exclusion of close differentials, confirmation and formal classification requires correlation with a complete work-up—including clonal plasma-cell studies, immunophenotyping, and genomic-biochemical staging. In the era of modern ‘quadruple therapies’ that add an antiCD-38 monoclonal antibody, besides an immunomodulatory drug, a proteasome inhibitor and a steroid, the International Myeloma Working Group (IMWG) Consensus Genomic Staging (CGS) in 2025 formally transitioned MM risk stratification into two distinct cohorts: "High-Risk" and "Standard-Risk" per five genomic-biochemical definitive criteria to guide intensive, risk-adapted therapeutic strategies. ‘Relapsed and refractory’ MM therapies now include anti-SLAMF7 monoclonal antibody, XPO1 inhibitor, Chimeric antigen receptor T-cells, and B-cell maturation antigen-directed therapies. In a 2026 published phase-3 trial, in ‘standard-risk newly diagnosed’ patients not receiving upfront autologous stem cell transplantation, Lenalidomide indefinite-duration maintenance medication following induction therapy did not significantly increase longer-term overall survival compared to fixed 2-year duration.

References

1. Koshiaris C. Methods for reducing delays in the diagnosis of multiple myeloma. Int J Hematol Oncol 2019;8(1):IJH13. https://doi.org/10.2217/ijh-2018-0014.

2. Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma. In: StatPearls [Internet]. n.p.: StatPearls Publishing, 2023. https://www.ncbi.nlm.nih.gov/sites/books/NBK534764/ (13 Oct. 2026, date last accessed).

3. Zorlu T, Kayer MA, Okumus N et al. Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma. Diagnostics 2025;15(13):1708. https://doi.org/10.3390/diagnostics15131708.

4. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128(23):2599–606. https://doi.org/10.1182/blood-2016-09-692954.

5. Kyle R, Durie B, Rajkumar S et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121–7. https://doi.org/10.1038/leu.2010.60.

6. A historical perspective on milestones in multiple myeloma research - Ribatti - 2018 - European Journal of Haematology - Wiley Online Library. n.d. https://onlinelibrary.wiley.com/doi/10.1111/ejh.13003 (13 Oct. 2026, date last accessed).

7. Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-548. https://doi.org/10.1016/S1470-2045(14)70442-5.

8. Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-548. https://doi.org/10.1016/S1470-2045(14)70442-5.

9. Walker MD, Shane E. Hypercalcemia: A Review. JAMA 2022;328(16):1624–36. https://doi.org/10.1001/jama.2022.18331.

10. Shale WT, Jirata TD, Enawgaw MC et al. Rare Classic Presentation of Primary Hyperparathyroidism: A Case Report and Literature Review. Open Access Surg 2023;16:121–30. https://doi.org/10.2147/OAS.S433529.

11. Helbing A, Leslie SW, Levine SN. Primary Hyperparathyroidism. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2026. http://www.ncbi.nlm.nih.gov/books/NBK441895/ (21 Sept. 2026, date last accessed).

12. Helbing A, Leslie SW, Levine SN. Primary Hyperparathyroidism. In: StatPearls [Internet]. n.p.: StatPearls Publishing, 2026. https://www.ncbi.nlm.nih.gov/sites/books/NBK441895/ (10 Oct. 2026, date last accessed).

13. Goldner W. Cancer-Related Hypercalcemia. J Oncol Pract 2016;12(5):426–32. https://doi.org/10.1200/JOP.2016.011155.

14. Seccareccia D. Cancer-related hypercalcemia. Can Fam Physician 2010;56(3):244–6.

15. Piechota P, Masajtis-Zagajewska A, Jerzmanowska-Piechota K et al. Hypercalcemia associated with kidney disease: it is not always what you think—a case report. J Med Case Reports 2026;20:157. https://doi.org/10.1186/s13256-026-05860-z.

16. Diagnostic approach to hypercalcemia - UpToDate. n.d. https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia (12 Oct. 2026, date last accessed).

17. El-Ashwah S, Eisa N, Denewer M et al. Hypercalcemia With Disseminated Osteolytic Lesions: A Rare Presentation of Adulthood Acute Lymphoblastic Leukemia. J Hematol 2018;7(4):154–7. https://doi.org/10.14740/jh455w.

18. Almuradova E, Cicin I. Cancer-related hypercalcemia and potential treatments. Front Endocrinol 2023;14. https://doi.org/10.3389/fendo.2023.1039490.

19. Akbar U, Ahmad O, Sajjad F et al. Brown Tumors Mimicking Skeletal Metastases: A Diagnostic Pitfall in Primary Hyperparathyroidism. Clin Case Rep 2025;13(12):e71543. https://doi.org/10.1002/ccr3.71543.

20. Rai S, Rattan V, Bhadada SK. Giant Cell Lesions Associated with Primary Hyperparathyroidism. J Maxillofac Oral Surg 2015;14(4):930–4. https://doi.org/10.1007/s12663-014-0719-4.

21. Liu Y, Zheng Y, Ding S. The correlation between serum calcium levels and prognosis in patients with severe acute osteomyelitis. Front Immunol 2024;15:1378730. https://doi.org/10.3389/fimmu.2024.1378730.

22. Dukmak ON, Abualia SMS, Meqbil YJI et al. Eosinophilic granuloma affecting the parietal bone of the skull: A case report and literature review. Int J Surg Case Rep 2022;96:107371. https://doi.org/10.1016/j.ijscr.2022.107371.

23. Khandwala HM, Boctor MA. Multiple Myeloma Presenting with Recurrent Hypercalcemia in a Patient aith a History of Primary Hyperparathyroidism: Report of Case and Review of Literature. Endocr Pract 2004;10(4):345–7. https://doi.org/10.4158/ep.10.4.345.

24. Gomez CK, Schiffman SR, Bhatt AA. Radiological review of skull lesions. Insights Imaging 2018;9(5):857–82. https://doi.org/10.1007/s13244-018-0643-0.

25. Kundu S, Jha SB, Rivera AP et al. Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management. Cureus n.d.;14(2):e22585. https://doi.org/10.7759/cureus.22585.

26. Heher EC, Rennke HG, Laubach JP et al. Kidney Disease and Multiple Myeloma. Clin J Am Soc Nephrol CJASN 2013;8(11):2007–17. https://doi.org/10.2215/CJN.12231212.

27. Silvestris F, Tucci M, Quatraro C et al. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol 2003;78(2):121–5. https://doi.org/10.1007/BF02983379.

28. Light chain cast nephropathy. n.d. https://www.pathologyoutlines.com/topic/kidneylightchaincastnephropathy.html (14 Oct. 2026, date last accessed).

29. Ndamase S, Freercks R. The utility of urine sulphosalicylic acid testing in the detection of non-albumin proteinuria. SAMJ South Afr Med J 2015;105(2):153–153. https://doi.org/10.7196/samj.9270.

30. O’Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician 2005;71(1):105–12.

31. Abduh MS. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities. Saudi J Biol Sci 2024;31(2):103920. https://doi.org/10.1016/j.sjbs.2023.103920.

32. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2024;99(9):1802–24. https://doi.org/10.1002/ajh.27422.

33. International Myeloma Foundation. International Staging System (ISS) and Revised ISS (R-ISS). n.d. https://www.myeloma.org/international-staging-system-iss-reivised-iss-r-iss (10 Oct. 2026, date last accessed).

34. Multiple myeloma: Staging and prognostic studies - UpToDate. n.d. https://www.uptodate.com/contents/multiple-myeloma-staging-and-prognostic-studies (12 Oct. 2026, date last accessed).

35. Multiple myeloma: Overview of management - UpToDate. n.d. https://www.uptodate.com/contents/multiple-myeloma-overview-of-management (12 Oct. 2026, date last accessed).

36. Multiple Myeloma Treatments | Drugs & Treatment by Stage. MMRF n.d. https://themmrf.org/diagnosis-and-treatment/treatment-options/ (10 Oct. 2026, date last accessed).

37. Multiple myeloma: Management in resource-limited settings - UpToDate. n.d. https://www.uptodate.com/contents/multiple-myeloma-management-in-resource-limited-settings (12 Oct. 2026, date last accessed).

38. Kumar S, Jacobus S, Cohen A et al. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. N Engl J Med 2026;395(3):221–32. https://doi.org/10.1056/NEJMoa2600157.

Downloads

Published

2026-11-16

How to Cite

Liya K, B., Varghese, J., Kompithra, R. Z., & Abraham, J. (2026). Multiple Myeloma—The Great Masquerader: A Case Report and Narrative Review of Current Management Strategies . RESEARCH REVIEW International Journal of Multidisciplinary, 11(11), 01-14. https://doi.org/10.31305/rrijm.2026.v11.n11.001